BillionToOne
BillionToOne is a pioneering molecular diagnostics company committed to making highly accurate tests accessible globally. The company develops revolutionary technologies in prenatal and cancer diagnostics, aiming to transform standard care through innovative products.
Headquarters
Menlo Park, California, United States
Company Size
201-500 employees
Founded
2016
BillionToOne is a molecular diagnostics company that develops blood-based tests for prenatal screening and oncology, with a focus on detecting rare genetic variants in cell-free DNA. Its proprietary Quantitative Counting Template technology powers noninvasive prenatal screening and liquid biopsy assays used by healthcare providers and clinical laboratories. The company operates in the genomics and precision diagnostics industry.
BillionToOne Market Share Gains Raise Questions On Undervalued BLLN Stock
4 days ago
BillionToOne valued at $4.4 billion as shares surge in blockbuster Nasdaq debut
Nov 6, 2025
BillionToOne’s Single-Molecule Next-Generation Sequencing Platform Redefines Molecular Diagnostics for Prenatal and Oncology Care 404148
9 hours ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for BillionToOne.
14% above the average for this role
BillionToOne Shares Surge Following Firm's $273M IPO
Nov 6, 2025
GRAIL Galleri Consultant 1 (Nashville, TN East)
GRAIL
Senior Staff Scientist, IVD Assay Verification and Validation (Contract)
DELFI Diagnostics, Inc.
Clinical Laboratory Scientist II
DELFI Diagnostics, Inc.
Oncology Account Executive - AL/MS
Biotheranostics
GRAIL Galleri Consultant 1 - (Twin Cities)
GRAIL
Senior Staff Clinical Data Manager
DELFI Diagnostics, Inc.